Discovery of LHRH and development of LHRH analogs for prostate cancer treatment. Issue 9 (27th April 2017)

• Record Type: Journal Article
• Authors: Schally, Andrew V.; Block, Norman L.; Rick, Ferenc G.
• Is Part Of: Prostate. Volume 77:Issue 9(2017)
• Page Start: 1036
• Page End: 1054
• Publication Date: 2017-04-27
• Subjects: advanced prostate cancer -- androgen deprivation therapy -- CRPC -- luteinizing hormone‐releasing hormone -- targeted therapy; Prostate -- Diseases -- Periodicals; 616
• DOI: 10.1002/pros.23360
• Languages: English
• ISSNs: 0270-4137

Abstract

Abstract : The discovery, isolation, elucidation of structure, synthesis, and initial testing of the neuropeptide hypothalamic luteinizing hormone‐releasing hormone (LHRH), which regulates reproduction, is briefly described. The design, synthesis, and experimental and clinical testing of agonistic analogs of LHRH is extensively reviewed focusing on the development of new methods for the treatment of prostate cancer. Subsequent development of antagonistic analogs of LHRH is then faithfully recounted with special emphasis on therapy of prostate cancer and BPH. The concepts of targeted therapy to peptide receptors on tumors are re‐examined and the development of the cytotoxic analogs of LHRH and their status is reviewed. The endeavor to develop better therapies for prostate cancer, based on LHRH analogs, guided much of our work.